HJ 115 PP
of 1965 (20 U.S.C. 1085(j))), including any
affiliate of such an agency; or
(v) an agency of any State functioning
as a student loan secondary market pursu-
ant to section 435(d)(1)(F) of the Higher
Education 
Act 
of 
1965 
(20 
U.S.C.
1085(d)(1)(F));
(B) a Government corporation (as defined
in section 9101 of title 31, United States Code);
(C) an organization of State or local elected
or appointed officials other than officials of an
entity described in clause (i), (ii), (iii), (iv), or
(v) of subparagraph (A);
(D) an Indian tribe (as defined in section
4(e) of the Indian Self-Determination and Edu-
cation Assistance Act (25 U.S.C. 450b(e));
(E) a national or State political party or
any organizational unit thereof; or
(F) a national, regional, or local unit of
any foreign government.
(17) STATE.—The term ‘‘State’’ means each of
the several States, the District of Columbia, and any
commonwealth, territory, or possession of the United
States.
HJ 115 PP
DISCLOSURE REQUIREMENTS
SEC. 302. (a) IN GENERAL.—Not later than December
31 of each year, each taxpayer subsidized grantee, except
an individual person, shall provide (via either electronic
or paper medium) to each Federal entity that awarded or
administered its taxpayer subsidized grant an annual re-
port for the previous Federal fiscal year, certified by the
taxpayer subsidized grantee’s chief executive officer or
equivalent person of authority, setting forth—
(1) the taxpayer subsidized grantee’s name and
grantee identification number;
(2) a statement that the taxpayer subsidized
grantee agrees that it is, and shall continue to be,
contractually bound by the terms of this title as a
condition of the continued receipt and use of Federal
funds; and
(3)(A) a statement that the taxpayer subsidized
grantee spent less than $25,000 on lobbying activities
in the grantee’s most recent taxable year; or
(B)(i) the amount or value of the taxpayer sub-
sidized grant (including all administrative and over-
head costs awarded);
(ii) a good faith estimate of the grantee’s actual
expenses on lobbying activities in the most recent tax-
able year; and
HJ 115 PP
(iii) a good faith estimate of the grantee’s al-
lowed expenses on lobbying activities under section
301 of this Act.
PUBLIC ACCOUNTABILITY
SEC. 303. (a) PUBLIC AVAILABILITY OF LOBBYING
DISCLOSURE FORMS.—Any Federal entity awarding a tax-
payer subsidized grant shall make publicly available any
taxpayer subsidized grant application, and the annual re-
port of a taxpayer subsidized grantee provided under sec-
tion 302 of this Act.
(b) ACCESSIBILITY TO PUBLIC.—The public’s access to
the documents identified in subsection (a) shall be facili-
tated by placement of such documents in the Federal enti-
ty’s public document reading room and also by expediting
any requests under section 552 of title 5, United States
Code, the Freedom of Information Act as amended, ahead
of any requests for other information pending at such Fed-
eral entity.
(c) WITHHOLDING PROHIBITED.—Records described
in subsection (a) shall not be subject to withholding, except
under the exemption set forth in subsection (b)(7)(A) of sec-
tion 552 of title 5, United States Code.
(d) FEES PROHIBITED.—No fees for searching for or
copying such documents shall be charged to the public.
(e) EFFECTIVE DATE.—The amendments made by this
title shall become effective January 4, 1996.
HJ 115 PP
TITLE IV—MEDICARE
SEC. 401. DETERMINATION OF MEDICARE PART B PRE-
MIUM.
(a) Any percentage reference in subsection (e)(1)(A)
of section 1839 of the Social Security Act for months in
1996 is deemed a reference to the amount described in
subsection (e)(1)(B)(v) of such section, expressed as a per-
centage of the monthly actuarial rate under subsection
(a)(1) of such section for months in 1995.
SEC. 402. MEDICARE COVERAGE OF CERTAIN ANTI-CANCER
DRUG TREATMENTS.
(a) COVERAGE
OF CERTAIN SELF-ADMINISTERED
ANTICANCER DRUGS.—Section 1861(s)(2)(Q) of the So-
cial Security Act (42 U.S.C. 1395x(s)(2)(Q)) is amend-
ed—
(1) by striking ‘‘(Q)’’ and inserting ‘‘(Q)(i)’’;
and
(2) by striking the semicolon at the end and in-
serting ‘‘, and’’; and
(3) by adding at the end the following:
‘‘(ii) an oral drug (which is approved by the Federal
Food and Drug Administration) prescribed for use as an
anticancer nonsteroidal antiestrogen or nonsteroidal
antiandrogen agent for a given indication;’’.
HJ 115 PP
(b) UNIFORM COVERAGE OF ANTICANCER DRUGS IN
ALL SETTINGS.—Section 1861(t)(2)(A) of such Act (42
U.S.C. 1395x(t)(2)(A)) is amended by adding (including
a nonsteroidal antiestrogen or nonsteroidal antiandrogen
regimen)’’ after ‘‘regimen’’.
(c) 
CONFORMING
AMENDMENT.—Section 
1834
(j)(5)(F)(iv) of such Act (42 U.S.C. 1395m(j)(5)(F)(iv))
is amended by striking ‘‘prescribed for use’’ and all that
follows through ‘‘1861 (s)(2)(Q))’’ and inserting ‘‘de-
scribed in section 1861(s)(2)(Q)’’.
(d) EFFECTIVE DATE.—The amendments made by
this section shall apply to drugs furnished on or after the
date of the enactment of this Act.
Passed the House of Representatives November 8,
1995.
Attest:
ROBIN H. CARLE,
Clerk.
Passed the Senate November 9, 1995.
Attest:
KELLY D. JOHNSTON,
Secretary.
HJ 115 PP——2
HJ 115 PP——3
HJ 115 PP——4
HJ 115 PP——5